Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.66 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.63 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.63 |
| ▸ | MMP1 | P03956 | 2/20 | 0.63 |
| ▸ | MMP2 | P08253 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.59 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenethylcarbamic Acid SCHEMBL9718519 | 0.98 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL4459966 | 0.98 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28010696 | 0.98 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28203613 | 0.96 | CA12 (0.63) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28210162 | 0.94 | CA12 (0.61) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL11405970 | 0.92 | EPHX1 (0.73) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL12478843 | 0.90 | SMN1; SMN2 (0.59) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28147202 | 0.90 | CA12 (0.58) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL1728418 | 0.88 | CNR1 (0.59) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL164622 | 0.87 | L3MBTL1 (0.72) | EPHX1NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| CN-112851671-B | 4-substituted pyrido [2,3-d ] pyrimidine-7-ketone compound and preparation method and application thereof | 南京思聚生物医药有限公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | claimed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1070076-A4 | CHIRAL SEPARATIONS OF PYRIMIDINES | CHIRAL TECHNOLOGIES INC (US) | 2002-05-29 | — | — | EP | claimed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | claimed |
| WO-2001034573-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | claimed |
| EP-1070076-A1 | CHIRAL SEPARATIONS OF PYRIMIDINES | Chiral Technologies, Inc. (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999047531-A1 | CHIRAL SEPARATIONS OF PYRIMIDINES | CHIRAL TECHNOLOGIES, INC. (US) | 1999-09-23 | — | — | WO | claimed |
| EP-0253372-B1 | 1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-09-28 | — | — | EP | claimed |
| EP-0085204-B1 | PROCESS FOR THE CO-PRODUCTION OF CARBOXYLIC ACIDS AND CARBOXYLIC ACID ESTERS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-02-12 | — | — | EP | claimed |
| EP-0031385-A1 | PROCESS FOR PREPARING POLYMETHYLENEPOLYPHENYL POLYCARBAMATE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CA12 2958/4885CA2 1724/4885CA9 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.